You are viewing a javascript disabled version of the site. Please enable Javascript for this site to function properly.
Go to headerGo to navigationGo to searchGo to contentsGo to footer
In content section. Select this link to jump to navigation

Erratum to: Inflammatory breast cancer with excellent response to pembrolizumab-chemotherapy combination: A case report

Article type: Correction

Authors: Kharel, Zenia; | Nemer, Omar P.b | Xi, Wangc | Upadhayaya, Bimalad | Falkson, Carla I.d | O’Regan, Ruth M.d | Dhakal, Ajayd

Affiliations: [a] Department of Internal Medicine, Rochester General Hospital, Rochester, NY, USA | [b] Department of Radiology, University of Rochester Medical Center, Rochester, NY, USA | [c] Department of Pathology, University of Rochester Medical Center, Rochester, NY, USA | [d] Department of Medicine, University of Rochester Medical Center, Rochester, NY, USA

Correspondence: [*] Corresponding author: Zeni Kharel, E-mail: [email protected]

DOI: 10.3233/BD-229001

Journal: Breast Disease, vol. 41, no. 1, pp. 363-363, 2022

Published: 31 August 2022
Get PDF

[Breast Disease, 41(1) 2022, 255–260, 10.3233/BD-210041] https://content.iospress.com/articles/breast-disease/bd210041

On p. 258, the sentence “Pembrolizumab is a PD-L1 monoclonal antibody.” should read “Pembrolizumab is an anti-PD-1 monoclonal antibody.”

Show more